HEAL vs XLV

HEALCGlobal X HealthTech ETF

XLVAState Street Health Care Select Sector SPDR ETF

In short

HEAL Most health care ETFs are pharma giants in a trench coat. HEAL goes the other way: roughly 40 health technology names worldwide, tracked against Global X's own HealthTech index, in a cohort built mostly of broad sector funds.

XLV Live since 1998, XLV is the original way to own health care: about 60 S&P 500 names, a 0.08% fee, and one of the busiest tickers in the sector. Big pharma and device makers, not small-cap biotech.

Stated mandate

HEAL The Fund seeks to track, before fees and expenses, the price and yield performance of the Global X HealthTech Index.

XLV The fund seeks to track, before expenses, the price and yield performance of the Health Care Select Sector Index, which represents the health care sector of the S&P 500 Index.

Why people hold it

• HEAL Focused by design. Roughly 40 holdings on a global mandate, so the health technology theme actually drives returns instead of being diluted by the whole sector.
• Rules-based, not manager-driven: it tracks the Global X HealthTech Index before fees and expenses, so what you own follows a published methodology rather than someone's conviction list.
• Global reach. Health technology innovation is not a US-only story, and the mandate is worldwide rather than fenced into the S&P 500 like several of the biggest sector options.
• A standard 1940 Act ETF wrapper holding equities. No leverage, no derivatives overlay, no K-1 surprises at tax time.

• XLV 0.08% a year against a cohort median of 0.50%. That ties it with FHLC as the cheapest in the group and edges VHT at 0.09%.
• One of the most actively traded funds in its category, which generally keeps bid-ask spreads thin whether you trade 10 shares or 10,000.
• Launched December 1998 as one of the first US sector funds, and it has tracked its S&P 500 health care index closely ever since.
• Covers the whole sector in one line: pharma, devices, providers, biotech, life-science tools and health tech. Pays quarterly.ssga.com

Worth knowing

• HEAL The 0.50% expense ratio sits right at the cohort median, but it is several times what the broad sector anchors charge: VHT at 0.09%, XLV and FHLC at 0.08%. Focus costs money here.
• Concentration cuts both ways. With about 40 names in one theme, individual holdings move the fund far more than they would in a several-hundred-stock health care index.
• It is one of the smaller and less actively traded funds in its peer group, which typically means wider bid-ask spreads than the household-name sector ETFs.

• XLV Cap-weighted and about 60 names deep, so the largest drug and device makers carry most of the weight.ssga.com
• S&P 500 members only. Mid- and small-cap health care names sit outside the mandate.
• One sector, one set of headlines: drug pricing rules, patent expirations and policy shifts move the whole basket together.

Full HEAL profile⁠

Full XLV profile⁠